AACR Cancer Progress Report 2018: References

1. American Association for Cancer Research. AACR Cancer Progress Report 2014. Clin Cancer Res 2014;20(Supplement 1):S1–S112.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.

3. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975-2015, National Cancer Institute. Bethesda, MD, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Available from: https://seer.cancer.gov/csr/1975_2015/.  

4. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2018;124:2785–2800.

5. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151–210.

6. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer rroups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018 Jun 2. [Epub ahead of print].

7. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: Internal Agency for Research on Cancer; 2013 [cited 2018 Aug 2]. Available from: http://globocan.iarc.fr.  

8. Making cancer data count. Lancet 2014;383:1946.

9. Kochanek KD, Murphy SL, Xu J, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017 Dec;293:1–8.

10. American Cancer Society. Cancer facts & figures 2018. Atlanta: American Cancer Society;2018.

11. National Cancer Institute. Cancer health disparities definitions. Available from: https://www.cancer.gov/about-nci/organization/crchd/about-health-disparities/definitions.  

12. Nahleh Z, Otoukesh S, Mirshahidi HR, Nguyen AL, Nagaraj G, Botrus G, et al. Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics. Cancer Med 2018;7:2710–7.

13. American Cancer Society. Breast cancer facts & figures 2017-2018. Atlanta: American Cancer Society;2018.

14. Wilson RJ, Ryerson AB, Singh SD, King JB. Cancer incidence in Appalachia, 2004–2011. Cancer Epidemiol Biomarkers Prev 2016;25:250–8.

15. Challapalli SD, Simpson MC, Adjei Boakye E, Pannu JS, Costa DJ, Osazuwa-Peters N. Head and neck squamous cell carcinoma in adolescents and young adults: survivorship patterns and disparities. J Adolesc Young Adult Oncol 2018 May 10. [Epub ahead of print].

16. Lin D, Gold HT, Schreiber D, Leichman LP, Sherman SE, Becker DJ. Impact of socioeconomic status on survival for patients with anal cancer. Cancer 2018;124:1791–7.

17. Cochran SD, Mays VM. Risk of breast cancer mortality among women cohabiting with same sex partners: findings from the National Health Interview Survey, 1997-2003. J Womens Health (Larchmt) 2012;21:528–33.

18. AACR Cancer Progress Report 2017. Philadelphia: American Association for Cancer Research; 2017. Available from: http://cancerprogressreport.org.  

19. 2017 National Population Projections Datasets [Internet]. U.S. Census Bureau. Washington, DC. 2017. Available from: https://www.census.gov/data/datasets/2017/demo/popproj/2017-popproj.html.  

20. Schiller JS, Clarke TC, Norris T. Early release of selected estimates based on data from the January-September 2017 National Health Interview Survey. National Center for Health Statistics. March 2018. Available from: https://www.cdc.gov/nchs/data/nhis/earlyrelease/EarlyRelease201803.pdf.

Top of page

21. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 2017;68:31–54.

22. Union for International Cancer Control. The economics of cancer prevention and control. Data Digest. 2014. Available from: http://issuu.com/uicc.org/docs/wcls2014_economics_of_cancer_final?e=10430107/10454633.  

23. Collins FS, Anderson JM, Austin CP, Battey JF, Birnbaum LS, Briggs JP, et al. Basic science: Bedrock of progress. Science 2016;351:1405.

24. Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010-2016. Proc Natl Acad Sci USA 2018;115:2329–34.

25. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature 2017;551:92–4.

26. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature 2018;555:321–7.

27. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 2018;555:371–6.

28. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78–85.

29. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78–81.

30. Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Murata M. Crosstalk between DNA damage and inflammation in the multiple steps of carcinogenesis. Int J Mol Sci 2017;18 pii:E1808.

31. American Association for Cancer Research. AACR Cancer Progress Report 2015. Clin Cancer Res 2015;21(Supplement 1):S1–128.

32. Dawson MA. The cancer epigenome: Concepts, challenges and therapeutic opportunities. Science 2017;355:1147–52.

33. McGranahan N, Swanton C. Clonal Heterogeneity and tumor evolution : past, present, and the future. Cell 2017;168:613–28.

34. Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 2016;538:518–22.

35. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett 2016;380:205–15.

36. American Association for Cancer Research. AACR Cancer Progress Report 2016. Clin Cancer Res 2016;22(Supplement 1):S1–137.

37. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 2018;173:321–37.

38. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 2018;173:305–20.

39. American Association for Cancer Research. AACR Cancer Progress Report 2013. Clin Cancer Res 2013;19(Supplement 1):S1–88.

40. Emmons KM, Colditz GA. Realizing the potential of cancer prevention - the role of implementation science. N Engl J Med 2017;376:986–90.

Top of page

41. Li Y, Pan A, Wang DD, Liu X, Dhana K, Franco OH, et al. Impact of healthy lifestyle factors on life expectancies in the US population. Circulation 2018 Apr 30. [Epub ahead of print].

42. Harris Insights & Analytics. National cancer opinion survey ASCO. Prepared for American Society of Clinical Oncology, October 2017. Available from: https://www.asco.org/sites/new-www.asco.org/files/content-files/research-and-progress/documents/ASCO-National-Cancer-Opinion-Survey-Results.pdf.  

43. Drope J, Liber AC, Cahn Z, Stoklosa M, Kennedy R, Douglas CE, et al. Who’s still smoking? Disparities in adult cigarette smoking prevalence in the United States. CA Cancer J Clin 2018;68:106–15.

44. Akinboro O, Olorunfemi O, Basak P, Phillips E, Pomerantz D, Bernhardt B, et al. Secondhand smoke exposure among community-dwelling adult cancer survivors in the United States: 1999-2012. Cancer Epidemiol Biomarkers Prev 2017;26:1296–305.

45. Steele CB, Thomas CC, Henley SJ, Massetti GM, Galuska DA, Agurs-Collins T, et al. Vital Signs : Trends in incidence of cancers associated with overweight and obesity - United States, 2005-2014. MMWR Morb Mortal Wkly Rep 2017;66:1052–8.

46. Vaeth PA, Wang-Schweig M, Caetano R. Drinking, alcohol use disorder, and treatment access and utilization among U.S. racial/ethnic groups. Alcohol Clin Exp Res 2017;41:6–19.

47. Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016. MMWR Morb Mortal Wkly Rep 2017;66:874–82.

48. Barrow TM, Klett H, Toth R, Böhm J, Gigic B, Habermann N, et al. Smoking is associated with hypermethylation of the APC 1A promoter in colorectal cancer: the ColoCare Study. J Pathol 2017;243:366–75.

49. Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O’Hagan HM, et al. Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations. Cancer Cell 2017;32:360–76.

50. Centers for Disease Control and Prevention. Cancer and tobacco use. CDC Vital Signs, November, 2016. Available from: https://www.cdc.gov/vitalsigns/cancerandtobacco/index.html.  

51. Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. Mutational signatures associated with tobacco smoking in human cancer. Science 2016;354:618–22.

52. U.S. Department of Health and Human Services. The health consequences of smoking-50 years of progress: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.

53. Inoue-Choi M, Liao LM, Reyes-Guzman C, Hartge P, Caporaso N, Freedman ND, et al. Association of long-term, low-intensity smoking with all-cause and cause-specific mortality in the National Institutes of Health-AARP Diet and Health Study. JAMA Intern Med 2016;177:87–95.

54. Jamal A, Phillips E, Gentzke AS, Homa DM, Babb SD, King BA, et al. Current cigarette smoking among adults - United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:53–9.

55. Hahn EJ, Rayens MK, Wiggins AT, Gan W, Brown HM, Mullett TW. Lung cancer incidence and the strength of municipal smoke-free ordinances. Cancer 2018;124:374–80.

56. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008;35:158–76.

57. Christensen CH, Rostron B, Cosgrove C, Altekruse SF, Hartman AM, Gibson JT, et al. Association of cigarette, cigar, and pipe use with mortality risk in the US population. JAMA Intern Med 2018;178:469–76.

58. Wang TW, Gentzke A, Sharapova S, Cullen KA, Ambrose BK, Jamal A. Tobacco product use among middle and high school students - United States, 2011-2017. MMWR Morb Mortal Wkly Rep 2018;67:629–33.

59. Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, et al. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res 2015;21:514–25.

60. U.S. Department of Health and Human Services. E-cigarette use among youth and young adults. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016.

Top of page

61. National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes. The National Academies Press; 2018. Available from: https://www.nap.edu/catalog/24952.  

62. Mantey DS, Cooper MR, Clendennen SL, Pasch KE, Perry CL. E-cigarette marketing exposure is associated with e-cigarette use among US youth. J Adolesc Health 2016;58:686–90.

63. Marynak K, Gentzke A, Wang TW, Neff L, King BA. Exposure to electronic cigarette advertising among middle and high school students - United States, 2014–2016. MMWR Morb Mortal Wkly Rep 2018;67:294–9.

64. Rubinstein ML, Delucchi K, Benowitz NL, Ramo DE. Adolescent exposure to toxic volatile organic chemicals from e-cigarettes. Pediatrics 2018;141:e20173557.

65. Rigotti NA, Chang Y, Tindle HA, Kalkhoran SM, Levy DE, Regan S, et al. Association of e-cigarette use with smoking cessation among smokers who plan to quit after a hospitalization. Ann Intern Med 2018;168:613–20.

66. Kulik MC, Lisha NE, Glantz SA. E-cigarettes associated with depressed smoking cessation: a cross-sectional study of 28 European Union countries. Am J Prev Med 2018;54:603–9.

67. Giovenco DP, Delnevo CD. Prevalence of population smoking cessation by electronic cigarette use status in a national sample of recent smokers. Addict Behav 2018;76:129–34.

68. Loukas A, Marti CN, Cooper M, Pasch KE, Perry CL. Exclusive e-cigarette use predicts cigarette initiation among college students. Addict Behav 2018;76:343–7.

69. Donohoe CL, Lysaght J, O’Sullivan J, Reynolds JV. Emerging concepts linking obesity with the hallmarks of cancer. Trends Endocrinol Metab 2017;28:46–62.

70. Trust for America's health. The state of obesity: better policies for a healthier America 2017. Robert Wood Johnson Foundation. 2017 Aug. Available from: https://stateofobesity.org/files/stateofobesity2017.pdf.  

71. Fiolet T, Srour B, Sellem L, Kesse-Guyot E, Allès B, Méjean C, et al. Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort. BMJ 2018;360:k322.

72. Lauby‑Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer - viewpoint of the IARC Working Group. N Engl J Med 2016;375:794–8.

73. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Body fatness and weight gain and the risk of cancer. Available from: dietandcancerreport.org.  

74. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015 – 2020 dietary guidelines for Americans. 8th Edition. December 2015: Available from: https://health.gov/dietaryguidelines/2015/guidelines/

75. American Cancer Society. Cancer prevention & early detection facts & figures 2017-2018. Atlanta: American Cancer Society; 2017.

76. Rosiner A, Herrick K, Gahche J, Park S. Sugar-sweetened beverage consumption among U.S. youth, 2011–2014. NCHS Data Brief 2017 Jan;271:1–8.

77. Kumar GS, Pan L, Park S, Lee-Kwan SH, Onufrak S, Blanck HM, et al. Sugar-sweetened beverage consumption among adults-18 States, 2012. MMWR Morb Mortal Wkly Rep 2014;63:686–90.

78. Chen D, Jaenicke EC, Volpe RJ. Food environments and obesity: Household diet expenditure versus food deserts. Am J Public Health 2016;106:881–8.

79. Allcott H, Diamond R, Dubé JP. The geography of poverty and nutrition: food deserts and food choices across the United States. Stanford University Graduate School of Business Research Paper No. 18-6. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3095779.

80. Xi B, Veeranki SP, Zhao M, Ma C, Yan Y, Mi J. Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in U.S. adults. J Am Coll Cardiol 2017;70:913–22.

Top of page

81. White AJ, DeRoo LA, Weinberg CR, Sandler DP. Lifetime alcohol intake, binge drinking behaviors, and breast cancer risk. Am J Epidemiol 2017;186:541–9.

82. LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ. Alcohol and cancer: A statement of the American Society of Clinical Oncology. J Clin Oncol 2018;36:83–93.

83. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013. JAMA Psychiatry 2017;74:911.

84. Kanny D, Naimi TS, Liu Y, Lu H, Brewer RD. Annual total binge drinks consumed by U.S. adults, 2015. Am J Prev Med 2018;54:486–96.

85. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Alcoholic drinks and the risk of cancer. Available from: dietandcancerreport.org.  

86. World Health Organization. Global status report on alcohol and health - 2014 ed. Available from: http://www.who.int/substance_abuse/publications/global_alcohol_report/msbgsruprofiles.pdf.  

87. Garaycoechea JI, Crossan GP, Langevin F, Mulderrig L, Louzada S, Yang F, et al. Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells. Nature 2018;553:171–7.

88. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;98121:1683–91.

89. Holman DM, Freeman MB, Shoemaker ML. Trends in melanoma incidence among non-Hispanic whites in the United States, 2005 to 2014. JAMA Dermatology 2018;154:361–2.

90. Watson M, Garnett E, Guy GP, Holman DM. The surgeon general’s call to action to prevent skin cancer: facts for consumers. Int J Cancer Res Prev 2015;8:55–161.

91. Guy GP Jr, Berkowitz Z, Everett Jones S, Watson M, Richardson LC. Prevalence of indoor tanning and association with sunburn among youth in the United States. JAMA Dermatol 2017;153:387–90.

92. Guy GP Jr, Watson M, Seidenberg AB, Hartman AM, Holman DM, Perna F. Trends in indoor tanning and its association with sunburn among US adults. J Am Acad Dermatol 2017;76:1191–3.

93. Guy GP Jr, Zhang Y, Ekwueme DU, Rim SH, Watson M. The potential impact of reducing indoor tanning on melanoma prevention and treatment costs in the United States: An economic analysis. J Am Acad Dermatol 2017;76:226–33.

94. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, et al. Behavioral counseling to prevent skin cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319:1134–42.

95. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016;4:e609–16.

96. Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med 2017;53:e31–3.

97. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human papillomavirus-associated cancers - United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2016;65:661–6.

98. Dempsey AF, Pyrznawoski J, Lockhart S, Barnard J, Campagna EJ, Garrett K, et al. Effect of a health care professional communication training intervention on adolescent human papillomavirus vaccination: a cluster randomized clinical trial. JAMA Pediatr 2018;172:e180016.

99. Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination. J Infect Dis 2018;217:1590–600.

100. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016;65:1405–8.

Top of page

101. Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, et al. Immunogenicity of the 9-Valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316:2411–21.

102. National Cancer Institute, NIH, DHHS. Cancer Trends Progress Report. Bethesda MD, 2018 Feb. Available from: https://progressreport.cancer.gov.  

103. Jagai JS, Messer LC, Rappazzo KM, Gray CL, Grabich SC, Lobdell DT. County-level cumulative environmental quality associated with cancer incidence. Cancer 2017;123:2901–8.

104. Nigra AE, Sanchez TR, Nachman KE, Harvey DE, Chillrud SN, Graziano JH, et al. The effect of the Environmental Protection Agency maximum contaminant level on arsenic exposure in the USA from 2003 to 2014: an analysis of the National Health and Nutrition Examination Survey (NHANES). Lancet Public Health 2017;2:e513–21.

105. US Prevention Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319:1901–13.

106. Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin 2018 May 30. [Epub ahead of print].

107. Roberts MC, Ferrer RA, Rendle KA, Kobrin SC, Taplin SH, Hesse BW, et al. Lay beliefs about the accuracy and value of cancer screening. Am J Prev Med 2018;54:699–703.

108. National Cancer Institute. Genetic testing for hereditary cancer syndromes. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet#q4.  

109. Campbell JD, Mazzilli SA, Reid ME, Dhillon SS, Platero S, Beane J, et al. The case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prev Res 2016;9:119–124.

110. Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, et al. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Res 2018;78:2747–59.

111. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, et al. Precancer atlas to drive precision prevention trials. Cancer Res 2017;77:1510–41.

112. Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, et al. Precision prevention and early detection of cancer: fundamental principles. Cancer Discov 2018;8:803–11.

113. Pham D, Bhandari S, Oechsli M, Pinkston CM, Kloecker GH. Lung cancer screening rates: data from the lung cancer screening registry. J Clin Oncol. 2018;36(suppl: abstr 6504).

114. White A, Thompson TD, White MC, Sabatino SA, de Moor J, Doria-Rose PV., et al. Cancer screening test use - United States, 2015. MMWR Morb Mortal Wkly Rep 2017;66:201–6.

115. American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019. Atlanta: American Cancer Society; 2017.

116. Singal AG, Gupta S, Skinner CS, Ahn C, Santini NO, Agrawal D, et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. JAMA 2017;318:806–15.

117. Miller DP Jr, Denizard-Thompson N, Weaver KE, Case LD, Troyer JL, Spangler JG, et al. Effect of a digital health intervention on receipt of colorectal cancer screening in vulnerable patients. Ann Intern Med 2018;168:550–7.

118. Padela AI, Malik S, Ally SA, Quinn M, Hall S, Peek M. Reducing Muslim mammography disparities: outcomes from a religiously tailored mosque-based intervention. Health Educ Behav 2018 Apr 1. [Epub ahead of print].

119. Schoenborn NL, Lee K, Pollack CE, Armacost K, Dy SM, Bridges JFP, et al. Older adults’ views and communication preferences about cancer screening cessation. JAMA Intern Med 2017;177:1121–8.

120. Mehta KM, Fung KZ, Kistler CE, Chang A, Walter LC. Impact of cognitive impairment on screening mammography use in older US women. Am J Public Health 2010;100:1917–23.

Top of page

121. Freedman RA, Keating NL, Pace LE, Lii J, McCarthy EP, Schonberg MA. Use of surveillance mammography among older breast cancer survivors by life expectancy. J Clin Oncol 2017;35:3123–30.

122. Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol 2017;11:87.

123. Goldberg KB, Blumenthal GM, Mckee AE, Pazdur R. The FDA Oncology Center of Excellence and precision medicine. Exp Biol Med (Maywood) 2018;243:308–12.

124. Shea M, Ostermann L, Hohman R, Roberts S, Kozak M, Dull R, et al. Regulatory watch: impact of breakthrough therapy designation on cancer drug development. Nat Rev Drug Discov 2016;15:152.

125. Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ 2015;351:h4633.

126. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65–74.

127. Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. N Engl J Med 2016;374:2001–3.

128. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017;377:62–70.

129. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726–36.

130. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 2016;36:185–98.

131. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720–6.

132. Colon-Otero G, Smallridge RC, Solberg LA Jr, Keith TD, Woodward TA, Willis FB, et al. Disparities in participation in cancer clinical trials in the United States: a symptom of a healthcare system in crisis. Cancer 2008;112:447–54.

133. Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol 2016;2:137–9.

134. Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002;20:2109–17.

135. Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003;21:830–5.

136. Klapheke A, Yap SA, Pan K, Cress RD. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol 2018;36:308.e19-308.e25.

137. Pezzi TA, Schwartz DL, Mohamed ASR, Welsh JW, Komaki RU, Hahn SM, al et. Barriers to combined-modality therapy for limited-stage small-cell lung cancer. JAMA Oncol 2018 Jan 4. [Epub ahead of print].

138. Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer 2017;123:1590–6.

139. Al-Qurayshi Z, Crowther JE, Hamner JB, Ducoin C, Killackey MT, Kandil E. Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective. Anticancer Res 2018;38:2897–901.

140. Yeboa DN, Xu X, Jones BA, Soulos P, Gross C, Yu JB. Trend in age and racial disparities in the receipt of postlumpectomy radiation therapy for stage I breast cancer: 2004-2009. Am J Clin Oncol 2016;39:568–74.

Top of page

141. National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Appropriate use of advanced technologies for radiation therapy and surgery in oncology: workshop summary. Washington, DC. National Academies Press; 2016 Mar.

142. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018;4:e173501.

143. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672–82.

144. Lyman GH, Somerfield MR, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract 2017;13:196–8.

145. Giuliano AE, Ballman KV., McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017;318:918–26.

146. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018;8:145–52.

147. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513–20.

148. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086–94.

149. Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 2015;1:931–41.

150. Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol 2015;1:918–30.

151. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:1049–60.

152. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:1040–8.

153. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy buided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111–21.

154. Morisset J. Somatostatin: one of the rare multifunctional inhibitors of mammalian species. Pancreas 2017;46:8–18.

155. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125–35.

156. Pryma D, Chin B, Noto R, Dillon J, Solnes L, White T, et al. Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study. J Clin Oncol 2018;36(suppl: abstr 4005).

157. Briot T, Roger E, Thépot S, Lagarce F. Advances in treatment formulations for acute myeloid leukemia. Drug Discov Today 2018 Jun 2. [Epub ahead of print].

158. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol 2016;34(15 Suppl 7000).

159. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

160. Stein EM, Dinardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722–31.

Top of page

161. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378:2386–98.

162. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740–53.

163. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017;390:555–66.

164. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659–67.

165. Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, et al. Abstract CT149: Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study. Cancer Res 2017;77(13 Suppl):Abstract nr CT149.

166. Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester Disease and Langerhans cell histiocytosis: analysis of data From the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 2018;4:384–8.

167. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875–84.

168. Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 2017;23:5218–24.

169. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638–46.

170. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523–33.

171. Kraus WL. PARPs and ADP-ribosylation: 50 years ... and counting. Mol Cell 2015;58:902–10.

172. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347–57.

173. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:1408–18.

174. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–703.

175. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol 2018;36:7–13.

176. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:603–15.

177. Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 2018;29:84–91.

178. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018;359:1361–5.

179. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439–48.

180. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.

Top of page

181. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Eng J Med 2017;377:2531–44.

182. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130(Suppl 1):577

183. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018;24:739–48.

184. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 2018;24:731–8.

185. Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res 2018;2018:2386187.

186. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018;24:20–8.

187. Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018;36:2267–80.

188. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987;328:267–70.

189. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293–7.

190. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541–7.

191. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985–8.

192. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–51.

193. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561–9.

194. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027–34.

195. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734–6.

196. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.

197. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–502.

198. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.

199. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–91.

200. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919–29.

Top of page

201. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017;18:623–30.

202. Rischin D, Migden MR, Chang A, Chung CH, Dunn L, Guminski A, et al. Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). J Clin Oncol 2018;36(15 suppl):9519.

203. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–90.

204. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 2016;17:e542–51.

205. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093–104.

206. American Cancer Society. Cancer treatment & survivorship facts & figures 2016-2017. Atlanta: American Cancer Society; 2016.

207. Centers for Disease Control and Prevention (CDC). Cancer survivorship—United States, 1971–2001. MMWR Morb Mortal Wkly Rep. 2004;53:526–9.

208. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016;25:1029–36.

209. Institute of Medicine of the National Academies. Cancer survivorship care planning fact sheet. 2005 Nov. Available from: http://www.nationalacademies.org/hmd/~/media/Files/ReportFiles/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition/factsheetcareplanning.pdf.   

210. Jacobsen PB, DeRosa AP, Henderson TO, Mayer DK, Moskowitz CS, Paskett ED, et al. Systematic review of the impact of cancer survivorship care plans on health outcomes and health care delivery. J Clin Oncol 2018;36:2088–100.

211. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet 2017;390:2569–82.

212. Are M, McIntyre A, Reddy S. Global disparities in cancer pain management and palliative care. J Surg Oncol 2017;115:637–41.

213. Kwan ML, Yao S, Lee VS, Roh JM, Zhu Q, Ergas IJ, et al. Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study. Breast Cancer Res Treat 2016;159:119–29.

214. Keegan THM, Li Q, Steele A, Alvarez EM, Brunson A, Flowers CR, et al. Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. Cancer Causes Control 2018;29:551–61.

215. El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW, et al. Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial. J Clin Oncol 2017;35:3714–21.

216. Greer JA, Jacobs JM, El-Jawahri A, Nipp RD, Gallagher ER, Pirl WF, et al. Role of patient coping strategies in understanding the effects of early palliative care on quality of life and mood. J Clin Oncol 2018;36:53–60.

217. May P, Normand C, Cassel J, Del Fabbro E, Fine RL, Menz R., et al. Economics of palliative care for hospitalized adults with serious illness: a meta-analysis. JAMA Intern Med 2018;178:820–9.

218. IOM (Institute of Medicine). 2015. Dying in America: improving quality and honoring individual preferences near the end of life. Washington, DC: The National Academies Press. Available from: http://www.nationalacademies.org/hmd/Reports/2014/Dying-In-America-Improving-Quality-and-Honoring-Individual-Preferences-Near-the-End-of-Life.aspx.  

219. Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018;19:370–81.

220. Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA 2018;320:167–76.

Top of page

221. Mao JJ, Xie S, Duhamel K, Bao T, Kantoff PW, Li QS, et al. The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: a randomized clinical trial. J Clin Oncol 2018;36(suppl: abstr 10001).

222. Arrieta O, Angulo LP, Núñez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martinez-López D, et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol 2013;20:1941–8.

223. Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med 2003;65:636–43.

224. Butow PN, Turner J, Gilchrist J, Sharpe L, Smith AB, Fardell JE, et al. Randomized trial of ConquerFear: a novel, theoretically based psychosocial intervention for fear of cancer recurrence. J Clin Oncol 2017;35:4066–77.

225. van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: The SWORD Study, a randomized controlled trial. J Clin Oncol 2017;35:2173–83.

226. Urech C, Grossert A, Alder J, Scherer S, Handschin B, Kasenda B, et al. Web-based stress management for newly idagnosed patients with cancer (STREAM): a randomized, wait-list controlled intervention study. J Clin Oncol 2018;36:780–8.

227. Hummel SB, van Lankveld JJDM, Oldenburg HSA, Hahn DEE, Kieffer JM, Gerritsma MA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2017;35:1328–40.

228. Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D'Andrea D, et al. Association of smoking status with recurrence, metastasis, and mortality among patients with localized prostate cancer undergoing prostatectomy or radiotherapy: a systematic review and meta-analysis. JAMA Oncol 2018;4:953–61.

229. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis. Cancer Epidemiol Biomarkers Prev 2014;23:1783–92.

230. Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013;19:1941–8.

231. Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical activity and cancer outcomes: a precision medicine approach. Clin Cancer Res 2016;22:4766–75.

232. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, et al. Association of exercise with mortality in adult survivors of childhood cancer. JAMA Oncol 2018 Jun 3. [Epub ahead of print].

233. Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, et al. Association of survival with adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors after colon cancer diagnosis. JAMA Oncol 2018;4:783–90.

234. Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS, et al. Fiber intake and survival after colorectal cancer diagnosis. JAMA Oncol 2018;4:71–9.

235. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243–74.

236. Committee on Key Challenge Areas for Convergence and Health; Board on Life Sciences; Division on Earth and Life Studies; National Research Council. Convergence: facilitating transdisciplinary integration of life sciences, physical sciences, engineering, and beyond. Washington, DC. National Academies Press; 2014 Jun.

237. Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health, Lawler M, Haussler D, Siu LL, Haendel MA, McMurry JA, et al. Sharing clinical and genomic data on cancer - the need for global solutions. N Engl J Med 2017;376:2004–6.

238. Basch E. Patient-reported outcomes - harnessing patients’ voices to improve clinical care. N Eng J Med 2017;376:105–8.

239. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 2017;318:197–8.

240. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature 2017;542:115–8.

Top of page

241. Chen PJ, Lin MC, Lai MJ, Lin JC, Lu HH, Tseng VS. Accurate classification of diminutive colorectal polyps using computer-aided analysis. Gastroenterology 2018;154:568–75.

242. Ehteshami Bejnordi B, Veta M, Johannes Van Diest P, van Ginneken B, Karssemeijer N, Litjens G, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA 2017;318:2199–210.

243. Wright AV, Nuñez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing nature’s toolbox for genome engineering. Cell 2016;164:29–44.

244. Baylis F, McLeod M. First-in-human phase 1 CRISPR gene editing cancer trials: are we ready? Curr Gene Ther 2017;17:309–19.

245. Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med 2018;10:pii:eaap8793.

246. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926–30.

247. Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 2018;359:592–7.

248. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017;357:1156–60.

249. Guthrie L, Gupta S, Daily J, Kelly L. Human microbiome signatures of differential colorectal cancer drug metabolism. NPJ Biofilms Microbiomes 2017;3:27.

250. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97–103.

251. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–7.

252. Goldberg KB, Blumenthal GM, Pazdur R. The first year of the Food and Drug Administration Oncology Center of Excellence. Cancer J 2018;24:127–31.

253. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG; Writing Committee for the AACR Task Force on Tobacco and Cancer. Tobacco and cancer: an American Association for Cancer Research policy statement. Cancer Res 2010;70:3419–30.

Top of page

American Association for Cancer Research Foundation
The AACR Cancer Progress Report is published by the American Association for Cancer Research (AACR). The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration.

Requests for permission to reuse or reprint any part of the Cancer Progress Report should be sent to permissions@aacr.org.

© 2018 AACR | 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106
215-440-9300 | aacr@aacr.org

The American Association for Cancer Research (AACR) is a 501(c)(3) registered nonprofit organization (23-6251648).
Other AACR Sites
AACR Website
AACR Foundation Website
Cancer Today Magazine
AACR Blog: Cancer Research Catalyst

Follow the AACR

Follow the AACR Foundation